Luteoloside Inhibits Proliferation of Human Chronic Myeloid Leukemia K562 Cells by Inducing G2/M Phase Cell Cycle Arrest and Apoptosis by Shao, Jun-Li et al.
Shao et al 
Trop J Pharm Res, January 2016; 15(1): 39  
 
Tropical Journal of Pharmaceutical Research January 2016; 15 (1): 39-45 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v15i1.6 
Original Research Article 
 
 
Luteoloside Inhibits Proliferation of Human Chronic 
Myeloid Leukemia K562 Cells by Inducing G2/M Phase Cell 
Cycle Arrest and Apoptosis 
 
Jun-Li Shao*, Hai-Rong Liang and Juan-Xiu Dai 
Dongguan Key Laboratory of Environmental Medicine, School of Public Health, Guangdong Medical University, Dongguan, 
Guangdong 523808, China 
 
*For correspondence: Email: sjl@gdmc.edu.cn; Tel: 0086-759-22896573 
 
Received: 1 October 2015        Revised accepted: 23 December 2015 
 
Abstract 
Purpose: To investigate the effects of luteoloside on the proliferation of human chronic myeloid 
leukemia K562 cells and whether luteoloside induces cell cycle arrest and apoptosis in K562 cells. 
Methods: Luteoloside’s cytotoxicity was assessed using a cell counting kit. Cell cycle distribution was 
analysed by flow cytometry after propidium iodide (PI) staining. Cell apoptosis was assayed with 
apoptosis detection kit and Hoechst staining followed by observation under a fluorescence microscope. 
The expression of cell cycle- and apoptosis-related proteins was examined by Western blot analysis. 
Results: Luteoloside inhibited the proliferation of K562 cells in a dose- and time- dependent manner 
(IC50 = 30.7 μM) with less toxicity in a normal human cell line (IC50 = 91.8 μM). Moreover, anti-
proliferative effect of luteoloside was accompanied with G2/M phase arrest（p ＜ 0.05 or p＜0.01） and 
apoptosis（p ＜ 0.01 or p ＜ 0.001）. Further studies revealed that the expression level of cyclinB1 was 
down-regulated by luteoloside treatment. Furthermore, luteoloside treatment also increased pro-
apoptotic protein Bax expression and decreased anti-apoptotic protein Bcl-2 expression. 
Conclusion: These results suggest that the inhibitory effect of luteoloside on K562 cell proliferation is 
associated with inducing G2/M phase arrest and apoptosis, and that luteoloside is worth further studying 
for anticancer potential. 
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Chronic myeloid leukemia (CML) is a malignant 
hematological disease characterized by the 
deregulated growth of myeloid leukemia cells in 
the bone marrow and their accumulation in the 
blood. The incidence of CML is 1 - 2 cases per 
100,000 adults, and CML accounts for 
approximately 15 % of newly diagnosed cases of 
leukemia in adults [1]. Furthermore, CML is still 
one of the most difficult malignant hematological 
diseases to treat. The current commonly used 
chemotherapies are often accompanied with 
various side-effects, such as anemia, 
hemorrhage, infection, fever, enlargement of the 
liver, spleen and lymph nodes, and ostealgia [2]. 
Therefore, it is required to find new anticancer 
agents with increased efficacy and decreased 
toxicity. 
  
Plant-derived compounds have attracted 
considerable attention in cancer 
chemoprevention and treatment because of their 
high efficiency and safety [3]. Luteoloside, a 
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natural flavone subclass derived from plants, has 
exhibited a series of biological activities, such as 
potential antibacterial and antifungal [4], free 
radical scavenging [5], anti-oxidative capabilities 
[6,7], protection effects against doxorubicin-
induced cardiotoxicity [8], and anticarcinogenic 
potential against colon carcinogenesis [5] and 
hepatocellular carcinoma [9,10], etc. However, 
the effects of luteoloside on blood malignancy 
have not been reported. 
 
Here we carried out a study on the cytotoxicity of 
luteoloside against human CML K562 cells. K562 
cells were derived from CML patient carrying a 
BCR-ABL mutation. The mutation gives poor 
response to treatment by deregulated apoptosis, 
proliferation and differentiation [11]. Since an 
important mechanism for anticancer agents is to 
trigger apoptosis [12] and cell cycle arrest [13] in 
cancer cells while disturbing their proliferation, 
we evaluated the effects of luteoloside on cell 
cycle and apoptosis together with cell growth of 
K562 cells. To further explain the underlying 
mechanism of luteoloside effects, the expression 
of cell cycle- and apoptosis-related regulatory 
proteins were assessed in K562 cells treated 




Cell culture, antibodies and chemicals 
 
Leukemia cell K562 and human normal cell 
HUVEC12 were cultured in RPMI-1640 and 
DMEM media respectively. All of them were 
cultured in the media supplemented with 10 % 
fetal bovine serum at 37 oC in a humidified 5 % 
CO2 atmosphere. Antibodies against cyclinB1, 
Bax and Bcl-2 were purchased from Cell 
Signaling (Boston, USA). NAPDH antibody and 
horseradish peroxidase-conjugated secondary 
antibody were purchased from Beyotime 
Biotechnology (Beijing, China). Cell Counting Kit-
8 (CCK-8) and annexinV-FITC apoptosis 
detection kit were purchased from DoJindo 
(Kumamoto, Japan).  
 
RNase A, propidium iodide (PI), dimethyl 
sulfoxide (DMSO) and Hoechst 33342 were 
purchased from Sigma-Aldrich (St. Louis, USA). 
RIPA lysis buffer and BCA protein assay kit were 
purchased from CWBIO Biotechnology (Beijing, 
China). Luteoloside was purchased from 
Shanghai Winherb Medical Technology Co., Ltd. 
(Shanghai, China). Luteoloside was dissolved in 
DMSO at 25, 50, 100 and 200 mM as stock 
solutions and stored at -20 oC, and diluted 1000 
times with media as work solution when used. 
 
Cell growth inhibition assay 
 
HUVEC12 cells were seeded into 96 well 
microtiter plate (3 × 103 cells per well), and 
allowed to attach for 16h. Then media were 
exchanged with fresh media containing 
luteoloside at the indicated concentrations. K562 
cells were seeded into 96 well microtiter plate (3 
× 103 cells per well) together with various 
concentrations of luteoloside. Cells treated with 
0.1 % DMSO were used as controls. After 
treatment for 48 and 72 h, the cytotoxicities of 
luteoloside against K562 and HUVEC12 cells 
were assessed using CCK-8 assay. Briefly, CCK-
8 reagent (10 μL) was added to each well and 
the cells were incubated for 2 h at 37 °C. 
Absorbance was then analysed on a microplate 
reader (BioTek Synergy2) at 450 nm. All 
experiments were done in triplicate. 
 
Cell cycle analysis 
 
K562 cells were treated with luteoloside for 48h 
at concentrations of 50 and 200 μM or for 24 and 
48 h at 50 μM. At the end of the treatment, the 
cells were collected by centrifugation (1000 rpm, 
5 min), washed twice with ice-cold PBS, and 
fixed in 75 % ethanol at -20 oC overnight. Then, 
cells were washed twice with ice-cold PBS 
containing 0.2 % TritonX-100, and stained with 
DNA-staining solution (50 μg/mL PI and 100 
μg/mL RNase A in PBS) in the dark for 30 min at 
room temperature. Finally, cells were analysed 
by a flow cytometer (Becton Dickinson, CA, 
USA). All experiments were in duplicate and 
repeated three times. 
 
Detection of apoptosis 
 
K562 cells were treated with luteoloside at 
different concentrations (50 and 200 μM) for 48 
or 72 h. Then, apoptosis was assayed with 
annexinV-FITC apoptosis detection kit following 
the manufacturer’s instructions. Briefly, cells 
were harvested by centrifugation, washed twice 
in PBS and re-suspended in binding buffer. 
AnnexinV-FITC and PI were then added to the 
cell suspension. After incubation for 15 min in the 
dark at room temperature, cells were diluted with 
binding buffer again and the ratio of apoptotic 
cells was measured within 1h with a flow 
cytometer. All experiments were measured in 
duplicate and repeated three times. 
 
Hoechst 33342 staining was performed to detect 
the alterations of nuclear morphology of K562 
cells after luteoloside treatment. Hoechst 33342 
was added to the treated cells at a final 
concentration of 10 μg/mL, and the cells were 
incubated for another 10 min at 37 oC. The 
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stained cells were then observed to examine the 
degree of nucleus condensation under a 
fluorescence microscope equipped with standard 
excitation filters (Nikon, Japan). 
 
Western blot analysis 
 
Cells treated with luteoloside at the indicated 
concentrations and for different incubation time 
were harvested, washed twice with ice-cold PBS 
and lysed in ice-cold RIPA buffer for 10 min on 
ice. The lysates were centrifuged at 12,000 rpm 
for 10 min at 4 oC, and supernatants were 
collected. Protein concentrations were 
determined with BCA protein assay kit. Equal 
amounts of protein sample (30 μg) were 
fractionated on SDS-PAGE, and electro-
transferred onto PVDF membranes (Millipore). 
After blocking with 5 % (w/v) non-fat dry milk in 
PBS for 1 h at room temperature, the 
membranes were incubated overnight at 4 °C 
with the specific primary antibodies with a 1:1000 
dilution. The membranes were washed and then 
further incubated with horseradish peroxidase-
conjugated secondary antibody (1:1000) for 2 h 
at room temperature. After the membranes were 
washed again, the protein bands were visualized 
using a chemiluminescence imaging method 
(Pierce ECL Western Blot Substrate). All blots 




Data are presented as mean ± standard 
deviation (SD). Significant differences between 
treated and untreated (control) cells were 
identified by Student’s t test. P < 0.05 was 
considered statistically significant. IC50 (half 
maximal inhibitory concentration) values were 




Luteoloside inhibited the proliferation of K562 
cells 
 
Anti-tumor drugs are often screened according to 
their cytotoxic effects on cell proliferation or 
viability. Therefore, we first investigated the 
effects of luteoloside on the proliferation of K562 
cells exposed to luteoloside at various 
concentrations and for different time interval. As 
shown in Fig 1, luteoloside significantly inhibited 
the proliferation of K562 cells in a concentration- 
and time-dependent manner. When K562 cells 
were treated for 72h, the IC50 value was 30.7 μM. 
Moreover, there were smaller cytotoxic effects of 
luteoloside on the normal cell line HUVEC12 at 
the tested concentrations, with an IC50 value of 
91.8 μM for 72 h treatment. 
 
Luteoloside induced cell cycle arrest at G2/M 
phase  
 
To investigate the mechanism behind the 
inhibition of cell growth by luteoloside, cell cycle 
analysis was conducted by flow cytometry. As 
shown in Fig. 2A, the percentage of G2/M phase 
increased as the concentration of luteoloside 
increased in the 48 h treatment, which was 28.0 
(p < 0.05) and 35.8 (p < 0.01) at 50 and 200 μM, 


























Figure 1: Effects of luteoloside on cell proliferation. Cells were treated with luteoloside at 25, 50, 100 and 200 μM 
for 48 and 72h. Cell viability was determined using CCK-8 assay. Data are the mean ± SD of three independent 
experiments 
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Fig. 2B shows that the percentage of G2/M 
phase increased with prolonged incubation time 
at 50 μM, which was 23.9 (p < 0.05) and 29.4 (p 
< 0.01) for 24 and 48 h treatment respectively, 
while that of the untreated cells was only 20.5. 
These results demonstrate that luteoloside 
induces G2/M phase cell cycle arrest in K562 
cells in a concentration- and time-dependent 
manner. 
 
Luteoloside-induced apoptosis  
 
Using flow cytometry after annexinV-FITC and PI 
staining, we evaluated whether luteoloside 
induced apoptosis in K562 cells. As it can be 
observed (Fig. 3A), luteoloside increased the 
number of total apoptotic cells 2.2-fold at 50 μM 
and 3.4-fold at 200 μM for 48h treatment and 
3.1-fold at 50 μM and 6.0-fold at 200 μM for 72h 
treatment. Therefore, apoptotic effects of 
luteoloside on K562 cells were in a dose- and 
time-dependent manner. Since cell apoptosis is 
accompanied with alterations of nuclear 
morphology, Hoechst 33342 staining was 
performed to detect alterations of nuclear 
morphology of K562 cells treated with 
luteoloside. As shown in Fig 3B, the nuclei of the 
control cells were uniformly stained, while the 
nuclei of the treated cells showed the typical 
characteristics of apoptosis, including condensed 




Figure 2: Effects of luteoloside on cell cycle distribution of K562 cells. (A) K562 cells were treated with 50 and 
200 μM luteoloside for 48h. (B) K562 cells were treated with 50 μM luteoloside for 24 and 48h. Treated cells were 
harvested and fixed in 75 % ethanol. Then, the cells were stained with PI and analysed using a flow cytometer. A 
representative profile is shown for each treatment. The data are the mean ± SD of three independent 
experiments. *p ＜ 0.05 and **p ＜ 0.01 indicate statistically significant differences versus control group 
 
Figure 3: Effects of luteoloside on apoptosis of K562 cells. (A) K562 cells were treated with 50 and 200 μM 
luteoloside and harvested at 48 and 72h. The cells were then analysed by flow cytometry after annexinV-FITC 
and PI staining. The data are the percentages of early and late apoptosis/necrosis cells (upper plus lower right 
quadrants), expressed as the mean ± SD of three independent experiments. Significant differences between 
treated cells and control cells are indicated as **p < 0.01 and ***p < 0.001. (B) The cells treated with luteoloside 
were stained with Hoechst 33342 and observed under a fluorescence microscope. Representative results from 
three independent experiments are shown 
A 
B 
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Luteoloside decreased cyclinB1 and Bcl-2 
expression and increased Bax expression 
 
Expression of the intracellular proteins related to 
G2/M phase arrest and apoptosis, such as 
cyclinB1, Bax and Bcl-2, was investigated to 
understand the mechanisms by which luteoloside 
inhibited K562 cells. As shown in Fig 4, the 
expression of cyclinB1 decreased in response to 
luteoloside treatment. The expression of the pro-
apoptotic protein Bax was upregulated markedly, 
while the expression of the anti-apoptotic protein 
Bcl-2 was suppressed by luteoloside at the 




Figure 4: Effects of luteoloside on cell cycle- and 
apoptosis-related protein expression in K562 cells. 
Cells were treated with luteoloside at the indicated 
concentrations for 24, 48 and 72h. Protein samples of 
the treated cells were subjected to Western blot 
analysis with anti-cyclinB1, Bax and Bcl-2 monoclonal 
antibodies. The levels of GAPDH served as internal 
control. Representative results from three independent 




Since rapid growth due to deregulated cell cycle 
and reduced apoptosis is the important property 
of cancer cells, inhibiting proliferation by 
arresting cell cycle progression and promoting 
apoptosis has been an important strategy for 
anticancer drugs and chemo-preventive agents 
[12,15-17]. In this study, it is revealed that 
luteoloside can induce cell cycle arrest and 
apoptosis concomitantly with growth suppression 
of K562 cells. Thus, luteoloside has exhibited its 
anti-cancer effects not only on solid tumors 
[5,9,10] but also on blood malignancy. 
 
Considering the side-effects of the current 
chemotherapy drugs, it is required to conduct 
research on agents with high efficiency and low 
toxicity. In this study, luteoloside showed high 
cytotoxicity on K562 cells in a dose- and time-
dependent manner with an IC50 of value of 30.7 
μM for 72 h treatment. In addition, toxicity 
evaluation on the normal cell HUVEC12 revealed 
only minor decrease in cell viability at the tested 
concentrations with an IC50 of 91.8 μM for 72 h 
treatment. In contrast, luteoloside suppressed 
proliferation of several hepatocellular carcinoma 
cells [10], colon carcinoma cell COLO 320 DM 
and normal cell VERO [5] also in a dose- and 
time-dependent manner with IC50 of about 75, 
112.4 and 724 μM, respectively, for 72 h 
incubation. Therefore, the cytotoxic effects of 
luteoloside on K562 are in high efficiency and 
specific to some extent.   
 
Reproducing healthy cells is strictly regulated 
due to rigorously and accurately controlled cell 
cycle. Control of the cell cycle is driven by the 
cyclin-dependent kinases (CDKs). Cells cannot 
enter S phase or M phase without CDK 
activation. In order to become catalytically active, 
CDKs need to bind to a cyclin subunit that acts 
as an activator [15]. CyclinB1 is one of main 
cyclins involved in the regulation of the transition 
from G2 to M phase during the cell cycle. 
Modification subsequent to CDK1 binding to 
cyclinB1 causes activation of the CDK1/cyclinB1 
complex and drives the cell into mitosis [18]. 
CylclinB1 is synthesized initially in late G1 phase 
and its content reaches a maximum in G2 phase. 
It was reported that some natural or chemical 
compounds that cause G2/M phase arrest 
involved the down-regulation of cyclinB1 [19,20]. 
In the present study, luteoloside treatment 
increased the cell number at G2/M phase, as 
confirmed by flow cytometry. Western blot 
analysis further revealed the decreased 
expression of cyclinB1. These results indicate 
that down regulation of cyclinB1 may contribute 
to luteoloside-induced G2/M arrest in K562 cells.   
 
Apoptosis, also known as programmed cell 
death, plays an important role in the regulation of 
development and homeostasis [21,22]. Cells 
undergoing apoptosis always show a series of 
characteristics including cell shrinkage, 
membrane blebbing, chromatin condensation, 
DNA fragmentation and, eventually, cellular 
breakdown into apoptotic bodies [23].  
 
Apoptosis occurs through two main pathways: 
the extrinsic pathway, known as death receptor 
pathway, and intrinsic pathway, known as 
mitochondria pathway [24]. Mitochondria play a 
central role as the key control point in the 
mitochondria pathway. Bcl-2 family proteins, 
outer mitochondrial membrane proteins, have 
been well known as crucial regulators in the 
mitochondria pathway. Based on function, they 
are divided into two subclasses, pro-apoptotic 
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Bcl-2 family proteins (Bax, Bak and Bad, etc.) 
and anti-apoptotic Bcl-2 family proteins (Bcl-2, 
Bcl-xL and Mcl-1, etc.). Whether mitochondria 
pathway is activated depends on the balance 
between pro- and anti-apoptotic Bcl-2 family 
proteins. High expression of pro-apoptotic Bcl-2 
family proteins can enhance the permeability of 
outer mitochondrial membrane and the 
consequent translocation of cytochrome c from 
the mitochondria to the cytoplasm, which 
provokes the downstream apoptotic events, while 
the anti-apoptotic Bcl-2 family proteins oppose 
the pro-apoptotic Bcl-2 family proteins [25-27]. 
Increasing Bax/Bcl-2 ratio often accompanies 
phytochemical-induced apoptosis through 
mitochondrial pathway in cancer cells [28-30]. 
 
In this study, luteoloside treatment triggered cell 
death of K562 cells by inducing apoptosis, which 
was confirmed by an increase in the percentage 
of total apoptotic cell population and the 
condensation or fragmentation of chromatin/ 
nuclei after luteoloside treatment. Further study 
displayed that the pro-apoptotic protein Bax 
increased and the anti-apoptotic protein Bcl-2 
decreased after luteoloside treatment. These 
results indicate that luteoloside-induced 
apoptosis is mediated by Bax and Bcl-2 through 
the mitochondrial pathway. However, it cannot be 
excluded that the extrinsic apoptotic pathway is 
involved in the luteoloside-induced apoptosis 
based on the present results. 
 
It should be noted that future studies are required 
to investigate more molecular events responsible 





Despite its preliminary characteristics, this study 
indicates that luteoloside has antitumor potentials 
due to its growth inhibitory effect, G2/M phase 
arrest and inducement of apoptosis. 
Furthermore, decreased cyclinB1 expression 
may contribute to G2/M phase cell cycle arrest. 
Besides, up-regulation of pro-apoptotic molecule 
Bax and down-regulation of anti-apoptotic 
molecule Bcl-2, demonstrate that intrinsic 
apoptotic pathway is one of the pathways 
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